JP2022528437A - ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 - Google Patents
ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 Download PDFInfo
- Publication number
- JP2022528437A JP2022528437A JP2021559916A JP2021559916A JP2022528437A JP 2022528437 A JP2022528437 A JP 2022528437A JP 2021559916 A JP2021559916 A JP 2021559916A JP 2021559916 A JP2021559916 A JP 2021559916A JP 2022528437 A JP2022528437 A JP 2022528437A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- methyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title abstract description 6
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 230000008707 rearrangement Effects 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 238000001890 transfection Methods 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 129
- -1 3-azabicyclo [3.1.0] hexane-3-yl Chemical group 0.000 claims description 69
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229940043355 kinase inhibitor Drugs 0.000 claims description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001650 tertiary alcohol group Chemical group 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000008521 reorganization Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000005494 pyridonyl group Chemical group 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 9
- 102000020233 phosphotransferase Human genes 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- 239000003480 eluent Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 101150077555 Ret gene Proteins 0.000 description 9
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- CRJQXLOMFQRQSP-UHFFFAOYSA-N 2-chloro-6-methyl-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(Cl)N=C(C)C=2)=N1 CRJQXLOMFQRQSP-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- BOEBREGIAQWKNH-UHFFFAOYSA-N CC1=CC(=NN1)NC2=NC(=NC(=C2)C)N3CC4CCC(C3)N4.Cl Chemical compound CC1=CC(=NN1)NC2=NC(=NC(=C2)C)N3CC4CCC(C3)N4.Cl BOEBREGIAQWKNH-UHFFFAOYSA-N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RYXJXPHWRBWEEB-UHFFFAOYSA-N 4-fluoro-1h-pyrazole Chemical compound FC=1C=NNC=1 RYXJXPHWRBWEEB-UHFFFAOYSA-N 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- MJOKPSMSYSDZIT-UHFFFAOYSA-N 6-(4-fluoropyrazol-1-yl)pyridine-3-carboxylic acid Chemical compound C1=CC(=NC=C1C(=O)O)N2C=C(C=N2)F MJOKPSMSYSDZIT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- QRBICWITCBBJIJ-UHFFFAOYSA-N C1=CC(=NN=C1C(=O)O)N2C=C(C=N2)F Chemical compound C1=CC(=NN=C1C(=O)O)N2C=C(C=N2)F QRBICWITCBBJIJ-UHFFFAOYSA-N 0.000 description 4
- WISJJCPWLOJARU-UHFFFAOYSA-N CC1=CC(=NC(=C1)N2CC3CCC(C2)N3)NC4=NNC(=C4)C.Cl Chemical compound CC1=CC(=NC(=C1)N2CC3CCC(C2)N3)NC4=NNC(=C4)C.Cl WISJJCPWLOJARU-UHFFFAOYSA-N 0.000 description 4
- SEIYMZPWMAMEAC-UHFFFAOYSA-N CN1C=C(C=N1)C2=NN=C(C=C2)C(=O)O Chemical compound CN1C=C(C=N1)C2=NN=C(C=C2)C(=O)O SEIYMZPWMAMEAC-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- FPKXYXKLOWAIOX-UHFFFAOYSA-N methyl 6-chloropyridazine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=N1 FPKXYXKLOWAIOX-UHFFFAOYSA-N 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QOEUPKQHBNTLMP-UHFFFAOYSA-N CC1=CC(=NC(=C1)Br)N2CC3CCC(C2)N3C(=O)OC Chemical compound CC1=CC(=NC(=C1)Br)N2CC3CCC(C2)N3C(=O)OC QOEUPKQHBNTLMP-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- IJXHLVMUNBOGRR-UHFFFAOYSA-N methyl nonanoate Chemical compound CCCCCCCCC(=O)OC IJXHLVMUNBOGRR-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- BTLKROSJMNFSQZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyrimidine Chemical compound CC1=CC(Cl)=NC(Cl)=N1 BTLKROSJMNFSQZ-UHFFFAOYSA-N 0.000 description 2
- CIDWWTCSJWQJQR-UHFFFAOYSA-N 2-bromo-6-fluoro-4-methylpyridine Chemical compound CC1=CC(F)=NC(Br)=C1 CIDWWTCSJWQJQR-UHFFFAOYSA-N 0.000 description 2
- BBRQFVMEKQQIPJ-UHFFFAOYSA-N 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-piperazin-1-ylpyrimidin-4-amine hydrochloride Chemical compound CC1=CC(=NN1)NC2=NC(=NC(=C2)C)N3CCNCC3.Cl BBRQFVMEKQQIPJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N Methyl nicotinate Natural products COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 102000050427 human RET Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- ITMAHDJHOXDZEL-UHFFFAOYSA-N methyl pyridazine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=N1 ITMAHDJHOXDZEL-UHFFFAOYSA-N 0.000 description 2
- 229960001238 methylnicotinate Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000000075 primary alcohol group Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZWYWWUBMBUVZMO-UHFFFAOYSA-N 2-(4-fluoropyrazol-1-yl)pyridine Chemical compound Fc1cnn(c1)-c1ccccn1 ZWYWWUBMBUVZMO-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1h-pyrazole Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000003341 Bronsted base Substances 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- SQIALQGZTQORPN-UHFFFAOYSA-N CC(C)(O)C(C)(C)O.CN1C=C(B(O)O)C=N1 Chemical compound CC(C)(O)C(C)(C)O.CN1C=C(B(O)O)C=N1 SQIALQGZTQORPN-UHFFFAOYSA-N 0.000 description 1
- GBLBJPZSROAGMF-RWYJCYHVSA-N CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 Chemical compound CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 GBLBJPZSROAGMF-RWYJCYHVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010071987 RET gene mutation Diseases 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HLYBWNNPVXFCPZ-UHFFFAOYSA-N methyl 6-fluoropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(F)N=C1 HLYBWNNPVXFCPZ-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 description 1
- HAOKKJHTFUZWIM-UHFFFAOYSA-N pyridin-1-ium-2-amine;chloride Chemical compound Cl.NC1=CC=CC=N1 HAOKKJHTFUZWIM-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 229940121610 selpercatinib Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
Description
本願は、発明の名称が「ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途」である、2019年4月12日に中国特許庁へ提出された中国特許出願201910294193.9に基づく優先権を主張し、その全内容は、全体として援用により本明細書に組み込まれる。
本発明は、医薬技術分野に関し、特に、新規ピペラジンアミド誘導体、及び該誘導体を含有する医薬組成物、及び治療剤、特に、選択的トランスフェクション再編成(RET)キナーゼ阻害剤としてのその用途に関する。
R1は、水素、C1-C3アルキル基又はC3-C6シクロアルキル基から選ばれ、前記C1-C3アルキル基及びC3-C6シクロアルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
X1は、CHまたはNから選ばれ、
R2は、水素またはC1-C6アルキル基から選ばれ、
R3は、水素、シアノ基、C1-C6アルキル基、C1-C5第一級アルコール基、C3-C7第三級アルコール基、C1-C3アルコキシ基、C3-C6シクロアルキル基及び-R9CO2R10から選ばれ、前記C1-C6アルキル基、C1-C5第一級アルコール基、C3-C7第三級アルコール基、C1-C3アルコキシ基及びC3-C6シクロアルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
又は、R2、R3は、それらが連結している炭素原子と一緒にアリール基を形成し、前記アリール基は、さらに1つまたは複数のハロゲン原子又はC1-C6アルキル基で任意選択的に置換され、
R9は、化学結合またはC1-C4アルキレン基から選ばれ、
R10は、水素またはC1-C6アルキル基から選ばれ、
X2、X3、X4は、CHまたはNから選ばれ、ここで、X2がNである場合には、X3及びX4のうちの最大1つがNであり、また、X2がCHである場合には、X3及びX4はいずれもCHであり、
R4、R4’、R5、R5’、R6、R6’、R7、R7’は、独立して水素、C1-C3アルキル基又はC1-C4アルコキシ基から選ばれ、前記C1-C3アルキル基は、さらに1つまたは複数の水酸基、カルボキシ基又はシアノ基で任意選択的に置換され、
又は、R4とR4’、R5とR5’、R6とR6’又はR7とR7’は、連結して一緒になって-(CH2)2-、-(CH2)3-、-CH(CH3)CH2-、-OCH2CH2又はは-CH2OCH2-を形成し、
又は、R4とR5、R4とR6、R4とR7、R4’とR5’、R4’とR6’、R4’とR7’、R5とR6、R5とR7、R5’とR6’、R5’とR7’、R6とR7又はR6’とR7’は、連結して一緒になって-(CH2)q-又は-(CH2OCH2)-を形成し、
又は、R4とR4’、R5とR5’、R6とR6’又はR7とR7’は、一緒に=Oを表し、
e環は、ピラゾリル基、ピリジル基、フェニル基若しくは3-アザビシクロ[3.1.0]ヘキサン-3-イルから選ばれ、
R8は、独立して水素、ハロゲン、シアノ基、C1-C3アルキル基、C1-C3アルコキシ基又はC3-C6シクロアルキル基から選ばれ、前記C1-C3アルキル基、C1-C3アルコキシ基及びC3-C6シクロアルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
mは、1または2であり、
nは、1、2または3であり、
qは、2または3である。)
本発明の詳細な説明
本発明の化合物の合成方法
方法1:
方法2:
R3がR3’’であり、かつ、R3’’がC1-C5第一級アルコール基である場合の式(I)で示される化合物は、式(I-b)化合物と還元試薬(NaBH4やLiAlH4など)を反応させることにより製造される式(I-d)化合物である。
R3がR3’’’であり、かつ、R3’’’がC3-C7第三級アルコール基である場合の式(I)で示される化合物は、式(I-b)化合物とヨウ化メチルマグネシウム又は臭化メチルマグネシウムを反応させることにより製造される式(I-e)化合物である。
実施例では、本発明の具体的な化合物の調製及び関連する構造同定のデータが示される。以下の実施例は、本発明を説明するために使用されているが、本発明を限定するものではないことに留意されたい。化合物の構造は、核磁気共鳴(NMR)及び質量分析(MS)によって確定された。1H NMRスペクトルは、Bruker装置(400MHz)で測定され、化学シフトをppmで表し、テトラメチルシラン内部標準(0.00ppm)を使用した。1H NMRの表現方法は、s=シングレット、d=ダブレット、m=マルチプレット、br=ブロード、dd=ダブルダブレット、dt=ダブルトリプレットを表す。結合定数が指定されている場合、その単位がHzである。質量分析には、FINNIGAN LCQAd(ESI)質量分析計(メーカー:Thermo、モデル:FinniganLCQ advantage MAX)を使用した。
実施例1
実施例2
実施例5
実施例6
実施例7
生物学的評価
測定例1、RETキナーゼ活性に対する本発明に係る化合物の測定
(1)受試化合物(本発明の化合物及び対照としてのWO2018017983A1の化合物164)を100%のDMSOに終濃度が10mMとなるように溶解した。
(2)46uLの100%DMSOで4uLのステップ(1)で調製した受試化合物溶液を溶解し、このステップで得られた溶液を2号の番号を付けた。
(3)2号の溶液を、希釈倍数を5倍(即ち20μLの100%のDMSOに5μLの化合物を加える)として、合わせて9つの段階となるように、段階希釈し、3号~11号の番号を付けた。
注:2号は、ステップ(4)の希釈に使用しない。
(特に断らない限り、次のステップはすべて氷上で行う必要がある)
(4)キット(Cisbio、カタログ番号62TK0PEB)で提供される緩衝液で3号~11号の溶液を段階希釈し、希釈倍数を20倍(即ち、3号~11号の溶液に19μLの緩衝液をそれぞれ加える)とした。ここで、3号~11号のシステムにおける受試化合物の終濃度範囲が3200nM~0.008nM(9つの段階)であり、DMSO終濃度が2%であった。
(5)ステップ(4)における9つの段階濃度の受試化合物溶液を濃度の順で384ウェルプレートにウェルあたり4μL加え、2つの重複ウェルを設定した。
(6)2μLのヒトRETタンパク質を各ウェルに加え、氷上で10分間インキュベートした。
(7)2μLのATP(Sigma#A7699)及び2μLのビオチン化ポリペプチド基質(Cisbio、カタログ番号62TK0PEB)を各ウェルに加え、リン酸化反応を開始した。37℃下で30分間インキュベートした。
(8)ユーロピウム系元素化合物とカップリングされた抗リン酸化チロシン抗体5μL(キットに提供された、カタログ番号62TK0PEB)及び修飾化アロフィコシアニンXL665とカップリングされたストレプトアビジン(Cisbio、カタログ番号62TK0PEB)5μLを各ウェルに加えた。
(9)室温下で1時間インキュベートし続けた。インキュベーション終了後、マイクロプレートリーダー(BMG Labtech、モデル:FLUOStar Omega)を使用してTF-FRETモードで励起波長を304nMとして各ウェルを測定し、各ウェルにおける発光波長が615nM及び665nMである蛍光強度を読み取って、比率を自動的に計算された。
(10)対照群の蛍光強度比と比較することにより、各濃度での化合物の阻害率を計算し、さらにGraphPad Prism5で対数濃度-阻害率でカーブフィッティングを行い、化合物のIC50値を計算した。その結果を表2に示す。
Claims (10)
- 下記の式(I)で示される化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩。
R1は、水素、C1-C3アルキル基若しくはC3-C6シクロアルキル基から選ばれ、前記C1-C3アルキル基及びC3-C6シクロアルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
X1は、CHまたはNから選ばれ、
R2は、水素またはC1-C6アルキル基から選ばれ、
R3は、水素、シアノ基、C1-C6アルキル基、C1-C5第一級アルコール基、C3-C7第三級アルコール基、C1-C3アルコキシ基、C3-C6シクロアルキル基及び-R9CO2R10から選ばれ、前記C1-C6アルキル基、C1-C5第一級アルコール基、C3-C7第三級アルコール基、C1-C3アルコキシ基及びC3-C6シクロアルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
或いは、R2、R3は、それらが連結している炭素原子と一緒にアリール基を形成し、前記アリール基は、さらに1つまたは複数のハロゲン原子又はC1-C6アルキル基で任意選択的に置換され、
R9は、化学結合またはC1-C4アルキレン基から選ばれ、
R10は、水素またはC1-C6アルキル基から選ばれ、
X2、X3、X4は、CHまたはNから選ばれ、X2がNである場合には、X3及びX4のうちの最大1つがNであり、X2がCHである場合には、X3及びX4はいずれもCHであり、
R4、R4’、R5、R5’、R6、R6’、R7、R7’は、独立して、水素、C1-C3アルキル基若しくはC1-C4アルコキシ基から選ばれ、前記C1-C3アルキル基は、さらに1つまたは複数の水酸基、カルボキシ基若しくはシアノ基で任意選択的に置換され、
或いは、R4とR4’、R5とR5’、R6とR6’若しくはR7とR7’は、連結して一緒になって-(CH2)2-、-(CH2)3-、-CH(CH3)CH2-、-OCH2CH2-若しくは-CH2OCH2-を形成し、
或いは、R4とR5、R4とR6、R4とR7、R4’とR5’、R4’とR6’、R4’とR7’、R5とR6、R5とR7、R5’とR6’、R5’とR7’、R6とR7又はR6’とR7’は、連結して一緒になって-(CH2)q-又は-(CH2OCH2)-を形成し、
或いは、R4とR4’、R5とR5’、R6とR6’又はR7とR7’は、一緒に=Oを表し、
e環は、ピラゾリル基、ピリジル基、フェニル基又は3-アザビシクロ[3.1.0]ヘキサン-3-イルから選ばれ、
R8は、独立して、水素、ハロゲン、シアノ基、C1-C3アルキル基、C1-C3アルコキシ基又はC3-C6シクロアルキル基から選ばれ、前記C1-C3アルキル基、C1-C3アルコキシ基及びC3-C6シクロアルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
mは、1または2であり、
nは、1、2または3であり、
qは、2または3である。) - 式中、R3は、水素、シアノ基、C1-C6アルキル基、-CH2OH、-C(CH3)2OH、C1-C3アルコキシ基、C3-C6シクロアルキル基及び-R9CO2R10から選ばれ、前記C1-C6アルキル基は、さらに1つまたは複数のハロゲン原子で任意選択的に置換され、
又はR2、R3は、それらが連結している炭素原子と一緒にアリール基を形成し、前記アリール基は、さらに1つまたは複数のハロゲン原子又はC1-C6アルキル基で任意選択的に置換され、
R9は、化学結合またはC1-C4アルキレン基から選ばれ、
R10は、水素またはC1-C6アルキル基から選ばれる、請求項1又は2に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩。 - 式中、前記R3は、水素、メチル基、トリフルオロメチル基、-CH2OH、-C(CH3)2OH、-COOH及び-COOMeから選ばれ、
或いは、R2、R3は、それらが連結している炭素原子と一緒にベンゼン環を形成する、請求項3に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩。 - 式中、前記R4、R4’、R5、R5’、R6、R6’、R7、R7’は、それぞれ独立して、水素、メチル基、-CH2OH及び-CH2CH2OHから選ばれ、
或いは、R4とR4’、R5とR5’、R6とR6’又はR7とR7’は、連結して一緒になって-(CH2)2-、-OCH2CH2-若しくは-CH2OCH2-を形成し、
或いは、R4とR5、R4とR6、R4とR7、R4’とR5’、R4’とR6’、R4’とR7’、R5とR6、R5とR7、R5’とR6’、R5’とR7’、R6とR7又はR6’とR7’は、連結して一緒になって-CH2OCH2-又は-(CH2)2-を形成する、請求項1~4のいずれか一項に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩。 - 式中、前記R8は、独立して水素、ハロゲン、シアノ基又はC1-C3アルキル基から選ばれ、
前記ハロゲンは、フッ素または塩素であることが好ましく、前記C1-C3アルキル基は、メチル基であることが好ましい、請求項1~5のいずれか一項に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩。 - 有効量の請求項1~7のいずれか一項に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩と、及び薬学的に許容されるキャリア、賦形剤若しくはそれらの組み合わせとを含有する、医薬組成物。
- トランスフェクション再編成キナーゼ阻害剤の製造における、請求項1~7のいずれか一項に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩、又は請求項8に記載の医薬組成物の使用。
- トランスフェクション再編成遺伝子に駆動される疾患を治療するための医薬品の製造における、請求項1~7のいずれか一項に記載の化合物、又はその立体異性体、互変異性体若しくはその薬学的に許容される塩、又は請求項8に記載の医薬組成物の使用であって、
前記疾患は、癌であることが好ましく、前記癌は、肺癌、甲状腺癌、結腸癌、乳癌又は膵臓癌であることが好ましい、使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910294193.9 | 2019-04-12 | ||
CN201910294193.9A CN111808077B (zh) | 2019-04-12 | 2019-04-12 | 哌嗪酰胺衍生物,其制备方法及其在医药上的用途 |
PCT/CN2020/083854 WO2020207419A1 (zh) | 2019-04-12 | 2020-04-09 | 哌嗪酰胺衍生物,其制备方法及其在医药上的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022528437A true JP2022528437A (ja) | 2022-06-10 |
JP7335972B2 JP7335972B2 (ja) | 2023-08-30 |
Family
ID=72750953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021559916A Active JP7335972B2 (ja) | 2019-04-12 | 2020-04-09 | ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220177450A1 (ja) |
EP (1) | EP3954680A4 (ja) |
JP (1) | JP7335972B2 (ja) |
CN (1) | CN111808077B (ja) |
TW (1) | TWI749518B (ja) |
WO (1) | WO2020207419A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117466901A (zh) * | 2022-07-23 | 2024-01-30 | 浙江海正药业股份有限公司 | 哌嗪酰胺衍生物的晶型及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123697A1 (ja) * | 2004-06-21 | 2005-12-29 | Astellas Pharma Inc. | キナゾリン誘導体 |
CN103242341A (zh) * | 2013-04-19 | 2013-08-14 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
WO2016127074A1 (en) * | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
WO2017161269A1 (en) * | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
WO2018017983A1 (en) * | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
JP2018535967A (ja) * | 2015-11-02 | 2018-12-06 | ブループリント メディシンズ コーポレイション | Retの阻害剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1715059A1 (en) * | 2005-04-21 | 2006-10-25 | Esbatech AG | Method for the identification of possibly harmful receptor tyrosine kinase (RTK) mutations and of inhibitors or medication directed against RTK mutants |
EA035049B1 (ru) * | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
AR109919A1 (es) * | 2016-10-10 | 2019-02-06 | Array Biopharma Inc | Compuestos pirazolo[1,5-a]piridina sustituida como inhibidores de ret quinasa |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
CN110709402B (zh) * | 2017-06-15 | 2022-05-10 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
-
2019
- 2019-04-12 CN CN201910294193.9A patent/CN111808077B/zh active Active
-
2020
- 2020-04-09 US US17/602,758 patent/US20220177450A1/en active Pending
- 2020-04-09 WO PCT/CN2020/083854 patent/WO2020207419A1/zh unknown
- 2020-04-09 EP EP20786768.0A patent/EP3954680A4/en active Pending
- 2020-04-09 JP JP2021559916A patent/JP7335972B2/ja active Active
- 2020-04-10 TW TW109112254A patent/TWI749518B/zh active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123697A1 (ja) * | 2004-06-21 | 2005-12-29 | Astellas Pharma Inc. | キナゾリン誘導体 |
CN103242341A (zh) * | 2013-04-19 | 2013-08-14 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
WO2016127074A1 (en) * | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
JP2018535967A (ja) * | 2015-11-02 | 2018-12-06 | ブループリント メディシンズ コーポレイション | Retの阻害剤 |
WO2017161269A1 (en) * | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
WO2018017983A1 (en) * | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
Non-Patent Citations (1)
Title |
---|
ACS MED. CHEM. LETT., vol. 8, JPN6022043880, 2017, pages 1224 - 1229, ISSN: 0004984134 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020207419A1 (zh) | 2020-10-15 |
CN111808077B (zh) | 2023-05-02 |
TW202104209A (zh) | 2021-02-01 |
US20220177450A1 (en) | 2022-06-09 |
EP3954680A1 (en) | 2022-02-16 |
JP7335972B2 (ja) | 2023-08-30 |
EP3954680A4 (en) | 2022-12-21 |
CN111808077A (zh) | 2020-10-23 |
TWI749518B (zh) | 2021-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6457623B2 (ja) | 2,4−二置換7H−ピロロ[2,3−d]ピリミジン誘導体、その製造方法および医薬における使用 | |
JP6267806B2 (ja) | 2,4−二置換ベンゼン−1,5−ジアミン誘導体およびその使用ならびにそれから製造される医薬組成物および薬用組成物 | |
AU2017208998B2 (en) | Bruton's tyrosine kinase inhibitors | |
AU2014225155B2 (en) | Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof | |
WO2015022926A1 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
JP6986032B2 (ja) | Jak阻害剤としてのピロロピリミジン化合物の結晶 | |
CN111499634B (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
US10085983B2 (en) | Azabicyclo derivatives, process for preparation thereof and medical use thereof | |
KR20200115583A (ko) | Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도 | |
WO2009099163A1 (ja) | Pi3k阻害剤としてのピロロピリミジン誘導体及びその用途 | |
KR20190032420A (ko) | Fgfr 억제제로서 사용되는 헤테로시클릭 화합물 | |
JP2022523477A (ja) | ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物 | |
CN113527299B (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
CN114940683A (zh) | Hpk1抑制剂及其用途 | |
JP7329510B2 (ja) | ピラゾロピリジノン化合物 | |
CN115073469B (zh) | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 | |
CN112094269B (zh) | 一类饱和六元环并杂环类化合物、制备方法和用途 | |
CN111499613B (zh) | N-甲酰胺衍生物、其制备方法及其在医药上的用途 | |
TW201900644A (zh) | Fgfr4抑制劑及其制備與應用 | |
JP7335972B2 (ja) | ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 | |
CN114907350A (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
CN116375712A (zh) | 双吗啉取代的杂环化合物及其医药用途 | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
WO2023187471A1 (en) | Heteroaryl derivative compounds, and uses thereof | |
CN115215861A (zh) | 一种芳杂环取代的炔烃类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211015 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230420 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230818 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7335972 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |